New anticoagulants in 2024: The development of factor XI and XIa inhibitors (notice n° 586899)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01935cam a2200217 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121143330.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bentounes, Nûn K. |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | New anticoagulants in 2024: The development of factor XI and XIa inhibitors |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 94 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Thrombosis remains one of the leading causes of death worldwide. The history of anticoagulation has evolved considerably, from non-specific drugs (i.e., heparins and vitamin K antagonists [VKAs]) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux, and direct oral anticoagulants [DOACs]). Over the past decade, DOACs have been widely used in clinical practice because of their ease of use, favorable pharmacological profile, and lack of need for laboratory monitoring. However, despite having a better safety profile than VKAs, their risk of causing hemorrhagic events remains and is a feared side effect. New anticoagulants targeting the contact phase of coagulation are currently being developed and could potentially prevent the risk of thrombosis without impairing hemostasis, thereby reducing the bleeding risk. Observational and preclinical data on factor XI (FXI) deficiency make FXI a promising therapeutic target. The aim of this review is to summarize the results of the various clinical trials available that focus on FXI/FXIa inhibition, and to highlight the challenges that this new therapeutic class of anticoagulants will face. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Melicine, Sophie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Céline Martin, Anne |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Smadja, David M. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gendron, Nicolas |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gendron, Nicolas |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Sang Thrombose Vaisseaux | Volume 36 | 5 | 2024-12-04 | p. 197-209 | 0999-7385 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-sang-thrombose-vaisseaux-2024-5-page-197?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-sang-thrombose-vaisseaux-2024-5-page-197?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux